ARCEDI Biotech ApS is a Danish biotech company involved in developing technologies for rare cell detection, a widely sought after application in the prenatal as well as cancer diagnostics.
ARCEDI Biotech has proprietary method to enrich fetal cells from circulating maternal blood with high efficiency. Once enriched, the fetal cells are analyzed by whole genome sequencing.
ARCEDI launched EVITA TEST COMPLETE, world's first and only cell-based NIPT which is currently being offered via 23 clinics in Denmark.
Company Details
- Employees
- 26
- Founded
- 2013
- Address
- Tabletvej 1, Vejle,7100,denmark
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.arcedi.com
- Keywords
- Rare Cell Detection, Circulating Fetal Cells, Innovation, Biotechnology, Prenatal Diagnosis, Noninvasive Prenatal Testing.
- HQ
- Vejle
Arcedi Biotech Questions
Arcedi Biotech's website is http://www.arcedi.com
Arcedi Biotech's LinkedIn profile is https://dk.linkedin.com/company/arcedi-biotech
Arcedi Biotech has
26 employees.
View email and phone details for 26
employees at Arcedi Biotech.
Arcedi Biotech's industry is
Biotechnology Research
Arcedi Biotech's top competitors are
Adcendo,
Bionordika Denmark A/s,
Bioxpedia A/s,
Gumlink A/s,
Cytovac Ab,
Immudex,
Bagger-Sørensen Equity,
Ah Diagnostics,
Dna Diagnostic A/s,
Nmd Pharma A/s.
Arcedi Biotech's categories are Biotechnology Research
Arcedi Biotech's founding year is 2013
